Zacks Research Brokers Reduce Earnings Estimates for PBYI

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Investment analysts at Zacks Research dropped their Q2 2025 earnings per share estimates for shares of Puma Biotechnology in a research note issued to investors on Wednesday, April 30th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.08 per share for the quarter, down from their previous forecast of $0.09. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s FY2025 earnings at $0.48 EPS, Q3 2026 earnings at $0.13 EPS and Q4 2026 earnings at $0.02 EPS.

Other analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research report on Friday, February 28th. StockNews.com downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday.

Puma Biotechnology Stock Performance

Puma Biotechnology stock opened at $3.21 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. Puma Biotechnology has a fifty-two week low of $2.23 and a fifty-two week high of $5.20. The stock has a fifty day moving average of $3.13 and a two-hundred day moving average of $3.03. The company has a market capitalization of $159.32 million, a price-to-earnings ratio of 6.69 and a beta of 1.29.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The company had revenue of $59.10 million for the quarter, compared to the consensus estimate of $52.50 million.

Institutional Trading of Puma Biotechnology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PBYI. JPMorgan Chase & Co. boosted its position in shares of Puma Biotechnology by 169.5% in the third quarter. JPMorgan Chase & Co. now owns 48,493 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 30,499 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Puma Biotechnology by 83.9% during the 4th quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 11,252 shares during the period. Barclays PLC increased its holdings in shares of Puma Biotechnology by 146.5% during the 3rd quarter. Barclays PLC now owns 78,021 shares of the biopharmaceutical company’s stock worth $199,000 after buying an additional 46,370 shares during the last quarter. Franklin Resources Inc. purchased a new position in shares of Puma Biotechnology in the 3rd quarter worth $41,000. Finally, State Street Corp boosted its holdings in Puma Biotechnology by 17.0% in the third quarter. State Street Corp now owns 601,542 shares of the biopharmaceutical company’s stock valued at $1,534,000 after acquiring an additional 87,504 shares during the last quarter. Hedge funds and other institutional investors own 61.29% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.